ArticleCancer chemotherapy and pharmacology2015

The novel β2-selective proteasome inhibitor LU-102 decreases phosphorylation of I kappa B and induces highly synergistic cytotoxicity in combination with ibrutinib in multiple myeloma cells.

Johannes Kraus et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.